Molecular features of high proliferation/low ER-related signaling breast cancers suggest more effective therapeutic strategies
13/11/2023
Oral SERDs in ER+/HER2- metastatic breast cancer, an analysis of ESR1 wild type/mutant subgroups
27/11/2023